I am in shock at how much the price of my different medications have dropped. In January of 2025 I paid $136 a month for one drug and it now costs $49! I can't believe it. Finally some relief for anyone that has to rely on medication.

This was done by a Trump Executive Order not our lame-ass Congress. From AI:

Most-Favored-Nation (MFN) Drug Pricing is a policy that aligns U.S. prescription drug prices with the lowest prices paid in other developed nations. First proposed in 2020 under the Trump administration, the policy was blocked by legal challenges. In May 2025, President Donald J. Trump signed Executive Order 14297, "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients", re-launching the initiative.

Under the 2025 framework:

The MFN price is defined as the second-lowest manufacturer-reported net price (adjusted for GDP per capita) in a basket of OECD countries, including the UK, France, Germany, Italy, Canada, Japan, Denmark, and Switzerland.

The policy targets brand-name drugs without generic or biosimilar competition and applies initially to Medicaid, with plans for expansion to Medicare, commercial markets, and direct-to-consumer (DTC) channels.

As of December 2025, nine major pharmaceutical manufacturers—including Pfizer, Amgen, Bristol Myers Squibb, GSK, Merck, Novartis, Sanofi, Genentech, and Gilead Sciences—entered voluntary agreements to implement MFN pricing.

These agreements include commitments to:

Provide every state Medicaid program access to MFN prices.

Launch direct-to-consumer purchasing programs via TrumpRx.gov.

Make newly launched drugs available at MFN prices across all U.S. markets.

Secure tariff relief (e.g., 3-year delay on Section 232 tariffs) and FDA Commissioner National Priority Vouchers (CNPVs) for faster drug reviews.

Invest billions in U.S. manufacturing and R&D (e.g., Pfizer’s $70 billion commitment).
On November 6, 2025, the Centers for Medicare & Medicaid Services (CMS) launched the GENErating cost Reductions fOr U.S. Medicaid (GENEROUS) Model, a pilot program using MFN pricing via supplemental rebates to state Medicaid programs. The model calculates MFN benchmarks using post-negotiation net prices, raising confidentiality concerns.

While proponents argue MFN pricing could reduce U.S. drug prices by 30% to 80%, critics warn of risks to innovation, supply chain stability, and legal challenges. The policy remains in early implementation, with ongoing monitoring by federal agencies and industry stakeholders.